New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

Amgen Inc.Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.

"The new Web site is designed to connect, engage and inspire Amgen Scholars on a global level by bringing together participants from diverse backgrounds and wide-ranging scientific career aspirations," said Jean J. Lim, president of the Amgen Foundation. "We hope that the online community will enrich the experience for all Amgen Scholars, not only during the program, but throughout their future careers in science."

The new Web site, launched in partnership with The Scientist, a leading life sciences magazine, allows current Amgen Scholars and alumni to login and access tools aimed at helping them build professional networks and read the latest science and career news. Through the use of interactive polls, message boards, personal profiles and blogs, users can discuss their participation in the program and various science-related topics such as graduate education and career paths in research. Others interested in the program can also view past participant and faculty mentor profiles and read excerpts of student blogs from the online community in the publicly-accessible section of the site.

2010 Amgen Scholars Program Applications Now Available
Established in 2006, Amgen Scholars is a $27.5 million initiative that provides undergraduates with the opportunity for hands-on research at some of the world's leading institutions. The opportunity to work with top academic scientists is a cornerstone of the program, with participating universities seeking to match students with faculty members who will both inspire and challenge them. In addition, the U.S. and Europe programs each host a three-day symposium allowing students to share their summer research projects and hear firsthand from leading industry and academic scientists.

To date, more than 800 undergraduates have participated in the Amgen Scholars Program. Considered among the most competitive summer research programs in the U.S., several Amgen Scholar alumni have gone on to pursue doctorates at leading universities with some being selected for premier fellowships including the Rhodes Scholarships.

In the U.S., the host universities are California Institute of Technology; Columbia University/Barnard College; Howard University; MIT; Stanford University; University of California, Berkeley; UCLA; University of California, San Diego; University of California, San Francisco; and University of Washington. In Europe, the participating universities are the University of Cambridge; Karolinska Institute; and Ludwig-Maximilians-University.

Financial support for students is a critical component of the U.S. and Europe programs, which aims to ensure that eligible students, regardless of their financial status, are able to participate. Please note that details vary by host university.

For more information about Amgen Scholars including eligibility criteria and applications, please visit www.amgenscholars.com.

About the Amgen Foundation
The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made $130 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts internationally.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...